DecImmune is developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/26/13 | $2,250,000 |
Astellas Venture Management Broadview Ventures Healthcare Ventures | undisclosed |
